Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07143669 · ClinicalTrials.gov registry record
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
A clinical trial of KIT D816V Mutation and Clonal Mast Cell Disease, sponsored by Blueprint Medicines Corporation.
- Recruiting
- Registry status
- 450
- Enrollment target
- 14
- Study locations
NCT07143669 is a study of KIT D816V Mutation and Clonal Mast Cell Disease that is actively recruiting participants, run by Blueprint Medicines Corporation. The registered enrollment target is 450 participants. The trial reports 14 study locations across 13 states.
The verdict
NCT07143669, a study of KIT D816V Mutation and Clonal Mast Cell Disease, is actively recruiting participants, sponsored by Blueprint Medicines Corporation.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
Conditions Studied
Interventions
- OTHER Screening
Study Locations (14)
California
- Kaiser Permanente San Diego - San Diego
- Allergy & Asthma Clinical Research of the Bay Area - Walnut Creek
Alabama
- AllerVie Clinical Research - Birmingham
Florida
- Allergy, Asthma, & Immunology Associates of Tampa Bay - Tampa
Georgia
- Emory University - Atlanta
Illinois
- Midwest Allergy Sinus Asthma - Normal
Maryland
- AllerVie Health - Glenn Dale
Missouri
- Barnes-Jewish West County Hospital - St Louis
Nebraska
- Somnos Clinical Research - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2028-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07143669
The ClinicalTrials.gov registry entry for NCT07143669 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with KIT D816V Mutation appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT07143669 reports 14 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT07143669 about?
NCT07143669 is a clinical study titled "Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations". This is a multicenter screening study to characterize the prevalence of the KIT D816V mutation in participants with suspected clonal mast cell disease.
What is the current status of trial NCT07143669?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2025-10-17. Estimated completion is 2028-10-31.
What conditions does trial NCT07143669 study?
This clinical trial studies the following conditions: KIT D816V Mutation, Clonal Mast Cell Disease, Suspected KITD816V Mutated Clonal Mast Cell Disease.
What interventions are being tested in trial NCT07143669?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT07143669?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07143669 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for KIT D816V Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.